Real-World Data: Policy Issues Regarding their Access and Use.

Med Care

*Pharmaceutical Outcome Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA †Pfizer Inc., New York, NY ‡Department of Health Care Policy at Harvard Medical School, Boston, MA §Departments of Medicine and Economics, and the School of Public Policy Studies, University of Chicago, IL ∥Departments of Medicine and Health Care Management at Wharton School, University of Pennsylvania, PA ¶The Fuqua School of Business, Duke University, Durham, NC #Harris School of Public Policy Studies, University of Chicago, Chicago, IL.

Published: December 2016

As real-world data (RWD) in health care begin to cross over to the Big Data realms, a panel of health economists was gathered to establish how well the current US policy environment further the goals of RWD and, if not, what can be done to improve matters. This report summarizes these discussions spanning the current US landscape of RWD availability and usefulness, private versus public development of RWD assets, the current inherent bias in terms of access to RWD, and guiding principles in providing quality assessments of new RWD studies. Three main conclusions emerge: (1) a business case is often required to incentivize investments in RWD assets. However, access restrictions for public data assets have failed to generate a proper market for these data and hence may have led to an underinvestment of public RWDs; (2) Very weak empirical evidence exist on for-profit entities misusing public RWD data entities to further their own agendas, which is the basis for supporting access restrictions of public RWD data; and (3) perhaps developing standardized metrics that could flag misuse of RWDs in an efficient way could help quell some of the fear of sharing public RWD assets with for-profit entities. It is hoped that these discussions and conclusions would pave the way for more rigorous and timely debates on the greater availability and accessibility of RWD assets.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MLR.0000000000000603DOI Listing

Publication Analysis

Top Keywords

rwd assets
16
public rwd
12
rwd
11
real-world data
8
access restrictions
8
restrictions public
8
for-profit entities
8
rwd data
8
data
6
public
6

Similar Publications

Article Synopsis
  • - As of September 2022, a lack of standardized core data elements for multiple sclerosis (MS) hindered effective data sharing and collaboration in healthcare and research.
  • - A global task force of 20 experts developed a core dataset of 44 variables in eight categories to improve data consistency from real-world data sources, which includes demographic information, disease history, MRI results, and treatment details.
  • - The resulting MS Data Alliance Core Dataset aims to assist newly formed and existing registries, promoting data harmonisation and improving research outcomes in the field of MS.
View Article and Find Full Text PDF

This research employs machine learning analysis on extensive data from a prominent Korean life insurance company to substantiate the insurance demand theory, which posits that insurance demand increases with risk aversion. We quantitatively delineate the traits of risk-averse individuals. Our study focuses on a cohort of 94,306 individuals who have filed insurance claims due to illness.

View Article and Find Full Text PDF

Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making.

Clin Pharmacol Ther

January 2023

Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.

Real-world data/evidence (RWD/RWE) may provide insightful information on medicines' clinical effects to guide regulatory decisions. While its contribution has been recognized for safety monitoring and disease epidemiology across medicines' life cycles, using RWD/RWE to demonstrate efficacy requires further evaluation. This study aimed to (i) characterize RWD/RWE presented by applicants to support claims on medicines' efficacy within initial marketing authorization applications (MAAs) and extension of indication applications (EoIs), and (ii) analyze the contribution of RWD/RWE to regulatory decisions on medicines' benefit-risk profile.

View Article and Find Full Text PDF

Canadian provinces routinely collect patient-level data for administrative purposes. These real-world data (RWD) can be used to generate real-world evidence (RWE) to inform clinical care and healthcare policy. The CanREValue Collaboration is developing a framework for the use of RWE in cancer drug funding decisions.

View Article and Find Full Text PDF
Article Synopsis
  • The Multiple Sclerosis Data Alliance (MSDA) aims to enhance the accessibility and discovery of real-world data (RWD) related to multiple sclerosis.
  • The MSDA Catalogue, which is globally available, compiles detailed information about various data sources, including governance and data quality control methods, and currently features 38 data sources from five continents.
  • The catalogue reveals trends in data collection, highlighting that personal and basic disease data are most commonly gathered, while aspects like fatigue and cognition measurements are less frequently recorded, ultimately aiding collaboration and reducing discovery times for MS RWD.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!